Page last updated: 2024-10-26

dichlorphenamide and Channelopathies

dichlorphenamide has been researched along with Channelopathies in 1 studies

Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.

Channelopathies: A variety of neuromuscular conditions resulting from MUTATIONS in ION CHANNELS manifesting as episodes of EPILEPSY; HEADACHE DISORDERS; and DYSKINESIAS.

Research Excerpts

ExcerptRelevanceReference
"Skeletal muscle ion channelopathies are rare genetic diseases mainly characterized by myotonia (muscle stiffness) or periodic paralysis (muscle weakness)."3.01Drug repurposing in skeletal muscle ion channelopathies. ( Altamura, C; Campanale, C; Desaphy, JF; Laghetti, P; Saltarella, I, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Altamura, C2
Saltarella, I2
Campanale, C2
Laghetti, P2
Desaphy, JF2

Reviews

1 review available for dichlorphenamide and Channelopathies

ArticleYear
Drug repurposing in skeletal muscle ion channelopathies.
    Current opinion in pharmacology, 2023, Volume: 68

    Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio

2023
Drug repurposing in skeletal muscle ion channelopathies.
    Current opinion in pharmacology, 2023, Volume: 68

    Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio

2023
Drug repurposing in skeletal muscle ion channelopathies.
    Current opinion in pharmacology, 2023, Volume: 68

    Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio

2023
Drug repurposing in skeletal muscle ion channelopathies.
    Current opinion in pharmacology, 2023, Volume: 68

    Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio

2023